Balloon Sinuplasty in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Adults (≥18 years) with a confirmed diagnosis of Chronic Rhinosinusitis (CRS) with or without nasal polyps (CRSwNP / CRSsNP), established by clinical history plus CT paranasal sinuses graded by the Lund-MacKay scoring system

• Patients who have failed a minimum 8–12 weeks of optimised medical therapy including topical corticosteroids, saline irrigation, and at least one course of appropriate systemic antibiotics

• Isolated or multi-sinus disease amenable to balloon dilation: maxillary (most common), frontal sinus recess, and sphenoid sinuses — confirmed on coronal and sagittal CT cuts

• Patients with CRS-associated anosmia, recurrent acute sinusitis (≥4 documented episodes/year), facial pain/pressure, nasal obstruction significantly impairing quality of life (SNOT-22 score ≥20)

• Patients seeking an outpatient, tissue-preserving alternative to conventional FESS, particularly those with comorbidities elevating general anaesthesia risk (ASA Class II–III)

• Paediatric consideration: selected adolescent patients (≥12 years) with anatomically mature sinuses, evaluated on an individual basis

• REQUIRED PRE-OPERATIVE DIAGNOSTICS:

• High-resolution CT Paranasal Sinuses (non-contrast, coronal + sagittal reformats) — mandatory for Lund-MacKay scoring and surgical planning

• Nasal endoscopy (rigid 0°/30° Hopkins rod or flexible nasopharyngoscopy) for direct mucosal assessment and polyp grading (Meltzer / Nasal Polyp Score)

• Allergy workup: skin prick testing or serum-specific IgE panel (Phadiatop, ISAC CRD) to identify allergic drivers of CRS

• Microbiological culture (endoscopically guided middle meatus swab or sinus aspirate) if bacterial CRS or fungal sinusitis (AFRS) suspected

• Full blood count, coagulation screen (PT/INR, aPTT), renal function panel — routine pre-operative assessment

• Olfactometry (UPSIT or Sniffin' Sticks) as a baseline quality-of-life measure and medico-legal documentation

• Sleep study (Level III home sleep apnoea test or in-lab PSG) if concurrent obstructive sleep apnoea is clinically suspected

• CONTRAINDICATIONS:

• Extensive sinonasal polyposis (Grade 3–4 bilateral polyps) occluding the entire nasal cavity — conventional FESS with microdebrider is preferred

• Sinonasal malignancy (must be excluded by MRI with gadolinium and biopsy before any sinus intervention)

• Severe septal deviation preventing endoscopic access (requires prior or concurrent septoplasty)

• Acute bacterial rhinosinusitis with orbital or intracranial extension (emergency drainage required)

• Uncorrected coagulopathy or therapeutic anticoagulation that cannot be safely bridged

• Aspirin-exacerbated respiratory disease (Samter's Triad) with severe polyposis — biological therapy (dupilumab, mepolizumab) should be optimised first

• Previous extensive sinus surgery with significant anatomical distortion that precludes safe balloon navigation

STANDARD APPROACH — OFFICE-BASED / AWAKE BALLOON SINUPLASTY (BSP):

Performed under topical anaesthesia (4% lidocaine-soaked pledgets) combined with targeted submucosal injection (1% lidocaine with 1:100,000 adrenaline) at the sphenopalatine ganglion and uncinate process. The Acclarent Relieva Spin or Entellus FinESS system — the two dominant FDA-cleared platforms — use a flexible fibre-optic guide catheter introduced transnasally to the sinus ostium, confirmed by transillumination through the sinus wall or fluoroscopic imaging. A nitinol guidewire is advanced into the sinus lumen, the balloon catheter is tracked over it, inflated to 10–12 atm for 5–10 seconds, and then deflated and withdrawn, leaving a permanently remodelled, widely patent ostium. The maxillary and sphenoid sinuses are most reliably treated by this awake approach. Total procedural time is typically 30–45 minutes for bilateral multi-sinus dilation.

ADVANCED APPROACH — HYBRID BSP WITH IMAGE-GUIDED NAVIGATION:

For complex anatomy (e.g., frontal sinus with narrow frontal recess, Kuhn cell variants, Agger Nasi hypertrophy), the Medtronic NuVent EM or Brainlab navigation system provides real-time electromagnetic tracking of the guidewire tip against the pre-loaded CT dataset, reducing the risk of orbital and skull-base violation to near zero. Hybrid procedures combine balloon dilation of primary ostia with microdebrider-assisted (Medtronic Straightshot M4 / Stryker Duet) removal of obstructing polyps, concha bullosa resection, or uncinate process trimming — performed under general or deep sedation anaesthesia in a formal operating theatre setting.

IN-OFFICE BSP WITH CONE-BEAM CT (CBCT) INTEGRATION:

Some high-volume ENT centres in India and the UAE now offer same-session CBCT (Carestream 9300 or Planmeca ProMax 3D) to confirm post-dilation ostial patency and detect residual obstruction before the patient leaves the procedure suite — a significant quality assurance advancement over fluoroscopy-only confirmation.

ADJUNCT BIOLOGICAL / PHARMACOLOGICAL THERAPIES:

For CRSwNP patients, pre-operative optimisation with dupilumab (IL-4Rα antagonist, 300 mg subcutaneous every 2 weeks) or mepolizumab (IL-5 antagonist) for 16 weeks prior to BSP significantly reduces polyp burden, improves intraoperative visibility, and is associated with lower post-operative recurrence rates at 12 months. Post-operatively, steroid-eluting implants (Intersect ENT Propel / Sinuwave) placed within the maxillary ostium at the time of balloon dilation deliver sustained mometasone furoate locally for 30 days, reducing post-operative synechia formation and inflammation — an option increasingly offered at premium centres in both India and the UAE.

COMPARISON — BSP vs. CONVENTIONAL FESS:

• Tissue preservation: BSP preserves all mucosa and bone; FESS involves partial or total uncinectomy, middle meatal antrostomy, and often ethmoidectomy

• Anaesthesia: BSP frequently performed awake or under moderate sedation; FESS almost always requires general anaesthesia

• Bleeding: BSP — minimal (< 5 mL); FESS — moderate (50–200 mL)

• Recovery: BSP — return to work 1–3 days; FESS — 1–2 weeks

• Revision surgery rates: BSP — 15% at 2 years; FESS — 10–12% at 2 years (BSP is slightly higher in polyp-dominant CRS, reflecting appropriate patient selection differences)

• Ideal patient profile for BSP: non-polyp CRS with primary ostial obstruction, mild-to-moderate CT disease (Lund-MacKay 4–12), patient preference for office setting

PRE-OPERATIVE PHASE (Weeks 1–3 before procedure):

• Week 1: GAF Healthcare coordinates remote CT paranasal sinus imaging review by the assigned ENT surgeon (DM or MS ENT, fellowship-trained in rhinology). A detailed teleconsultation is scheduled within 48 hours of CT upload.

• Week 1–2: Diagnostic workup completed — allergy panel, microbiological culture (if indicated), coagulation screen, and baseline SNOT-22 quality-of-life scoring. Anticoagulants (aspirin, warfarin, novel oral anticoagulants) are managed per institutional bridging protocol — typically held 5–7 days pre-operatively after haematology clearance.

• Week 2–3: Pre-operative nasal preparation: saline douching twice daily (Neil Med Sinus Rinse or equivalent), high-dose intranasal fluticasone furoate 110 mcg per nostril BD, and — in polyp-dominant cases — a 5–7 day pre-operative oral methylprednisolone taper to reduce mucosal oedema and optimise intraoperative access.

• 48 hours before: Patient arrives at destination city. GAF Healthcare airport transfer and hotel/serviced apartment check-in arranged. Pre-anaesthesia consultation and final ENT surgical assessment completed in-person.

PROCEDURE DAY:

• Admission: Day-care surgical unit or outpatient procedure room. Nil by mouth for 6 hours if sedation planned; topical anaesthesia-only cases may eat a light breakfast.

• Anaesthesia: Topical + submucosal infiltration for awake BSP; propofol TIVA (Total Intravenous Anaesthesia) or laryngeal mask airway general anaesthesia for hybrid/complex cases.

• Procedure duration: 30–60 minutes for standard bilateral BSP; 90–120 minutes for hybrid BSP with navigation and polypectomy.

• Intraoperative monitoring: Standard ASA monitoring (SpO₂, NIBP, ECG, EtCO₂). Image-guided navigation registered and confirmed before first guidewire insertion.

• Recovery room: 1–2 hours post-anaesthesia observation. Nasal packing is NOT routinely used after BSP (a key advantage over FESS). Patients are typically ambulatory and taking oral fluids within 2 hours.

• Discharge: Same-day discharge in >90% of cases. Oral analgesics (paracetamol 1g QDS + ibuprofen 400mg TDS), nasal saline rinses commenced immediately, intranasal corticosteroid continued.

POST-OPERATIVE RECOVERY TIMELINE:

• Days 1–3: Mild bloody nasal discharge (expected), nasal congestion due to mucosal oedema (peaks Day 2), facial pressure. Patients are instructed to avoid nose-blowing, strenuous activity, and air travel. Pain is typically mild (NRS 2–4) and well-controlled with oral analgesics.

• Days 3–7: Nasal congestion begins to resolve. First post-operative nasal saline irrigation (gentle, low-pressure) commenced Day 2–3. Clinic review (or telemedicine review for outstation patients) at Day 5–7 to assess for early synechia formation and confirm no epistaxis.

• Day 7–10: Nasal endoscopy review by surgeon to confirm ostial patency, debride any crusting, and assess mucosal healing. This is the key milestone for fit-to-fly clearance for short-haul flights (cabin pressure equivalent to 8,000 ft altitude is well-tolerated by Day 7–10 in uncomplicated BSP).

• Weeks 2–6: Gradual return to full activity. Monthly nasal endoscopy reviews recommended for 3 months. Intranasal corticosteroid spray continued indefinitely as maintenance.

• Month 3: Formal reassessment with repeat SNOT-22 scoring and flexible nasal endoscopy. CT paranasal sinuses repeated only if symptoms persist or recur.

• Month 12 and 24: Long-term surveillance visits or telemedicine reviews with GAF Healthcare-coordinated remote ENT follow-up in patient's home country.